All In Biotech

NDA 020688 · Alcon Labs INC

Pataday Twice Daily Relief

Olopatadine Hydrochloride · Ophthalmic

Novel

Last checked: Nov 19, 2026Latest source record: Apr 15, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Dec 18, 1996

Approved uses

3

Original approval plus efficacy supplements

Registered trials

63

22 Phase 3, 0 recruiting

FAERS reports

4,235

1,367 serious, 195 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 20, 2026.

Use temporarily relieves itchy and red eyes due to pollen, ragweed, grass, animal hair and dander

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 14, 2020 Supplement 32 · Efficacy LetterLabelReview
  • Mar 20, 2000 Supplement 12 · Efficacy · priority review Letter
  • Dec 18, 1996 Original approval · Type 1 - New Molecular Entity Review
1 products under this application
  • PATADAY TWICE DAILY RELIEF · OLOPATADINE HYDROCHLORIDE EQ 0.1% BASE · SOLUTION/DROPS, OPHTHALMIC · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Olopatadine" as an intervention, any sponsor and status, largest first.

All 63 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • treatment failure1,934
  • drug ineffective315
  • headache123
  • nausea117
  • diarrhoea114
  • fatigue104
  • pyrexia104
  • pneumonia103
  • malaise99
  • rash98
  • pruritus95
  • dyspnoea92

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20046
200510
20065
20078
200817
200918
201026
201125
201224
201330
201429
201549
201682
201791
2018131
2019191
20201,938
2021365
2022216
2023220
2024244
2025255
2026255

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 119 on PubMed

Sponsor: Alcon Labs INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.